FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2734401332> ?p ?o ?g. }

• W2734401332 endingPage "301" @default.
• W2734401332 startingPage "301" @default.
• W2734401332 abstract "Abstract ROR1 (Receptor tyrosine kinase-like orphan receptor 1) is an evolutionarily conserved, oncoembryonic antigen that is expressed on CLL cells, but not on normal postpartum tissues. In prior studies we found that ROR1 was a receptor for Wnt5a, which could activate RhoGTPases and enhance chemokine-directed leukemia-cell migration. Moreover, Wnt5a-enhanced migration could be inhibited by cirmtuzumab, a first-in-class humanized mAb specific for a functional epitope of the ROR1 extracellular domain; this mAb is undergoing phase I clinical testing in patients with CLL. However, it is not known whether ROR1 contributes to cell migration only through its recruitment/activation of guanine exchange factors (GEFs) or whether it also can complex with proteins that directly interact with the actin cytoskeleton. We performed mass spectrometry-based proteomics to interrogate immune-precipitates of Wnt5a-activated ROR1 from CLL cells and identified HS1 (or HCLS1, hematopoietic cell-specific Lyn substrate 1), a conserved cytoplasmic protein that can interact with the actin cytoskeleton. Moreover, tyrosine phosphorylation of HS1 has been found in prior studies to be associated with enhanced leukemia-cell migration and adverse prognosis in CLL, although the stimuli/mechanism(s) contributing to HS1 activation were unknown. We validated that Wnt5a induced the association of ROR1 with HS1 in primary CLL cells via co-immunoprecipitation studies and immunoblot analyses. Moreover, we found that Wnt5a could induce tyrosine phosphorylation of HS1 in CLL cells previously deprived of Wnt5a. On the other hand, treatment of CLL cells with the anti-ROR1 mAb cirmtuzumab inhibited the capacity of Wnt5a to induce the association of ROR1 with HS1 or tyrosine phosphorylation of HS1. We speculated that the Src-homology 3 (SH3) domain of HS1 allowed it to dock onto the cytoplasmic proline-rich domain (PRD) of ROR1. Consistent with this notion we found that a mutant-form of ROR1 lacking the PRD was unable to complex with HS1 or facilitate F-actin polymerization in response to Wnt5a. Accordingly, we used site-directed mutagenesis to introduce single amino acid substitutions of proline (P) to alanine (A) in the P-X-X-P- motifs of the ROR1 PRD at positions 784, 808, 826, 841, or 850. Each mutant form of ROR1, except for P841A-ROR1, could complex with HS1, permit tyrosine phosphorylation of HS1, and allow for enhanced leukemia-cell motility. Collectively, these data indicate that Wnt5a can induce HS1 to dock at P841 in the PRD of ROR1 and undergo tyrosine phosphorylation, thereby enhancing F-actin polymerization and planar-cell-polarity leukemia-cell migration. Moreover, we found that cirmtuzumab can inhibit activation of HS1 and F-actin polymerization in response to Wnt5a, potentially accounting in part for its capacity to inhibit Wnt5a-enhanced leukemia-cell migration. Disclosures Kipps: Gilead: Consultancy, Honoraria, Speakers Bureau; Pharmacyclics, LLC, an AbbVie Company: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Roche: Consultancy, Honoraria." @default.
• W2734401332 created "2017-07-21" @default.
• W2734401332 creator A5006335830 @default.
• W2734401332 creator A5010336471 @default.
• W2734401332 creator A5012296563 @default.
• W2734401332 creator A5033222332 @default.
• W2734401332 creator A5036294739 @default.
• W2734401332 creator A5036828560 @default.
• W2734401332 creator A5060928962 @default.
• W2734401332 creator A5063689808 @default.
• W2734401332 creator A5087255205 @default.
• W2734401332 date "2016-12-02" @default.
• W2734401332 modified "2023-09-26" @default.
• W2734401332 title "Wnt5a Induces ROR1 to Complex with HS1, Which Undergoes Tyrosine Phosphorylation and Contributes to Planar-Cell-Polarity Migration in Chronic Lymphocytic Leukemia" @default.
• W2734401332 doi "https://doi.org/10.1182/blood.v128.22.301.301" @default.
• W2734401332 hasPublicationYear "2016" @default.
• W2734401332 type Work @default.
• W2734401332 sameAs 2734401332 @default.
• W2734401332 citedByCount "2" @default.
• W2734401332 countsByYear W27344013322017 @default.
• W2734401332 countsByYear W27344013322018 @default.
• W2734401332 crossrefType "journal-article" @default.
• W2734401332 hasAuthorship W2734401332A5006335830 @default.
• W2734401332 hasAuthorship W2734401332A5010336471 @default.
• W2734401332 hasAuthorship W2734401332A5012296563 @default.
• W2734401332 hasAuthorship W2734401332A5033222332 @default.
• W2734401332 hasAuthorship W2734401332A5036294739 @default.
• W2734401332 hasAuthorship W2734401332A5036828560 @default.
• W2734401332 hasAuthorship W2734401332A5060928962 @default.
• W2734401332 hasAuthorship W2734401332A5063689808 @default.
• W2734401332 hasAuthorship W2734401332A5087255205 @default.
• W2734401332 hasConcept C11960822 @default.
• W2734401332 hasConcept C170493617 @default.
• W2734401332 hasConcept C175818844 @default.
• W2734401332 hasConcept C180361614 @default.
• W2734401332 hasConcept C23440912 @default.
• W2734401332 hasConcept C2775960820 @default.
• W2734401332 hasConcept C2776165026 @default.
• W2734401332 hasConcept C2777553839 @default.
• W2734401332 hasConcept C42362537 @default.
• W2734401332 hasConcept C502942594 @default.
• W2734401332 hasConcept C55493867 @default.
• W2734401332 hasConcept C62478195 @default.
• W2734401332 hasConcept C86803240 @default.
• W2734401332 hasConcept C95444343 @default.
• W2734401332 hasConceptScore W2734401332C11960822 @default.
• W2734401332 hasConceptScore W2734401332C170493617 @default.
• W2734401332 hasConceptScore W2734401332C175818844 @default.
• W2734401332 hasConceptScore W2734401332C180361614 @default.
• W2734401332 hasConceptScore W2734401332C23440912 @default.
• W2734401332 hasConceptScore W2734401332C2775960820 @default.
• W2734401332 hasConceptScore W2734401332C2776165026 @default.
• W2734401332 hasConceptScore W2734401332C2777553839 @default.
• W2734401332 hasConceptScore W2734401332C42362537 @default.
• W2734401332 hasConceptScore W2734401332C502942594 @default.
• W2734401332 hasConceptScore W2734401332C55493867 @default.
• W2734401332 hasConceptScore W2734401332C62478195 @default.
• W2734401332 hasConceptScore W2734401332C86803240 @default.
• W2734401332 hasConceptScore W2734401332C95444343 @default.
• W2734401332 hasIssue "22" @default.
• W2734401332 hasLocation W27344013321 @default.
• W2734401332 hasOpenAccess W2734401332 @default.
• W2734401332 hasPrimaryLocation W27344013321 @default.
• W2734401332 hasRelatedWork W1901641191 @default.
• W2734401332 hasRelatedWork W1966248035 @default.
• W2734401332 hasRelatedWork W1969541617 @default.
• W2734401332 hasRelatedWork W1993639183 @default.
• W2734401332 hasRelatedWork W2006535857 @default.
• W2734401332 hasRelatedWork W2061373449 @default.
• W2734401332 hasRelatedWork W2098527874 @default.
• W2734401332 hasRelatedWork W2130010008 @default.
• W2734401332 hasRelatedWork W2146874880 @default.
• W2734401332 hasRelatedWork W4313368740 @default.
• W2734401332 hasVolume "128" @default.
• W2734401332 isParatext "false" @default.
• W2734401332 isRetracted "false" @default.
• W2734401332 magId "2734401332" @default.
• W2734401332 workType "article" @default.